Status:
COMPLETED
Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease
Lead Sponsor:
University Hospital, Toulouse
Collaborating Sponsors:
French Parkinson Association
Conditions:
Parkinson's Disease
Eligibility:
All Genders
30-70 years
Phase:
PHASE3
Brief Summary
Patients suffering from Parkinson's disease (PD) frequently experienced painful sensations that could be, in part, due to a central modification of nociception mechanisms. Previous studies have shown ...
Eligibility Criteria
Inclusion
- Patients with clinical diagnosis of Parkinson's disease according to the criteria of the UKPDSBB
- Parkinson's disease patients with a score ≤ 3 on the Hoehn and Yahr scale
- Patients treated with dopaminergic antiparkinsonian drugs (L-Dopa, dopamine agonists, ICOMT…)
- Patients affiliated to a social protection program
- Women with efficacy contraception
Exclusion
- Patients suffering from another pathology causing chronic pain (rheumatic disease, traumatic or orthopedic pathologies…)
- Parkinson's disease patients with a score \> 3 on the Hoehn and Yahr scale
- Depressed patients (MADRS score \< 16)
- Patients suffering from a cancer
- Patients under tutelage, curatella or law protection
- Patients with a complete contraindication against apomorphine injections or duloxetine administration (selective serotonin reuptake inhibitor and monoamine oxydase inhibitors)
- Patients without any control of their arterial hypertension
- Patients with a neuroleptic treatment
- Pregnant women
Key Trial Info
Start Date :
May 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01504178
Start Date
May 1 2011
End Date
December 1 2015
Last Update
February 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CIC, Purpan Hospital
Toulouse, France, 31059